Dolutegravir is an antiretroviral medicine used primarily in the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection. The core therapeutic goal is to manage HIV by helping to reduce the amount of the virus in the body, which is referred to as the viral load.

---

What Dolutegravir treats: main uses and benefits

Dolutegravir is commonly used across conditions presenting with acute episodes. Its main use is in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed. The medication is applied in addressing distressing symptoms.

The medication is relevant in clinical contexts that involve heightened systemic burden, and is used for managing symptoms related to systemic imbalance and heightened physiological activity. By easing the overall symptom load, the medication contributes to maintaining functional stability of the immune system.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning
Dolutegravir provides supportive relief when symptoms interfere with routine activities, assisting with maintaining comfort during periods of heightened discomfort.

Regulatory References

1. European Medicines Agency (EMA) overview

Eligibility Scope for Dolutegravir Use

Official regulatory documents define specific populations who are permitted to use the medicine, as well as those for whom use is contraindicated or restricted.

Category	Regulatory Status (as stated in label)
Populations for whom use is allowed	Adults with HIV-1 infection. Pediatric patients (treatment-naïve or INSTI-naïve) aged at least four weeks and weighing at least 3 kg.
Populations for whom use is not recommended	Patients with severe hepatic impairment (Child-Pugh Class C). Use of certain fixed-dose combination products is not recommended with severe renal impairment (creatinine clearance <30 mL/min).
Populations for whom use is contraindicated	Patients with a prior hypersensitivity reaction to dolutegravir. Patients concurrently receiving the antiarrhythmic agent dofetilide (prohibited co-administration).
Age-related eligibility rules	Safety and efficacy are not established in pediatric patients younger than four weeks of age or weighing less than 3 kg. Older adults (ge 65 years) have limited data.
Pregnancy and lactation eligibility status	First Trimester/Periconception: Use is restricted or not recommended at the time of conception and through the first trimester of pregnancy due to the risk of Neural Tube Defects (NTDs) observed in some surveillance data. Lactation: Breastfeeding is not recommended due to the potential for HIV-1 transmission.

These classifications detail the specific conditions and populations that govern the medicine's approved use, establishing mandatory exclusions and conditional use populations based strictly on regulatory authority requirements.

Official Interaction Profile

Dolutegravir's interaction profile is defined by pharmacokinetic changes involving metabolic enzymes, renal transporters, and chelation.

Classification	Interacting Agents (Examples)	Official Regulatory Status
Contraindicated Combinations	Dofetilide, Fampridine (Dalfampridine)	Prohibited due to risk of serious adverse events from increased concentrations of co-administered drug.
Enzyme-Mediated Interaction	Rifampin, Carbamazepine, Phenytoin	Strong UGT1A1/CYP3A4 inducers decrease Dolutegravir exposure, necessitating a mandated dose adjustment.
Transporter-Mediated Effect	Metformin	Dolutegravir inhibits renal transporters OCT2/MATE1, leading to increased Metformin plasma concentrations.

Absorption Interference and Timing Constraints

Polyvalent cation-containing agents, including specific antacids (aluminum, magnesium), Sucralfate, and oral iron/calcium supplements, are officially documented to reduce Dolutegravir absorption via chelation. Regulatory documents mandate that Dolutegravir be administered 2 hours before or 6 hours after these agents when taken in a non-fed state. However, Dolutegravir and oral iron or calcium supplements can be administered simultaneously if taken with food.

Population-Specific Notes

The interaction with Metformin may increase the risk for lactic acidosis in patients with documented moderate renal impairment. Furthermore, official labeling states that substances known to decrease Dolutegravir exposure should be avoided in the presence of documented integrase class resistance.

Dolutegravir is an Integrase Strand Transfer Inhibitor ( INSTI) that acts by targeting a single, critical step in the HIV replication cycle. The drug binds directly to the active site of the viral Integrase (IN) enzyme when it is complexed with viral DNA. This interaction involves the chelation of essential divalent metal ions ( Mg^2+) located at the enzyme's catalytic center.

This high-affinity binding physically obstructs the strand transfer reaction, which is the final step required for the virus to permanently insert its genetic material into the host cell's DNA. By preventing the viral DNA from integrating into the host cell's genome, the formation of the provirus is blocked, which effectively halts the ability of the infected CD4^+ T-cells to produce new viral particles. This inhibition leads directly to a reduction in the systemic concentration of HIV-1 RNA (viral load).

Beyond its antiviral mechanism, Dolutegravir also engages an independent, ancillary mechanism by inhibiting the host renal Organic Cation Transporter 2 ( OCT2). This action reduces the secretion of endogenous creatinine by the kidney tubules, which results in an increase in measured serum creatinine levels.

Dolutegravir is administered exclusively by the oral route, available as a film-coated tablet or a dispersible tablet. The choice of dose and frequency is determined by the patient's treatment history and concurrent medications.

Official Dosing and Frequency Patterns

The standard regimen for adults with no known resistance to integrase inhibitors (INSTI-naïve) is 50 mg taken once daily. This once-daily pattern is the primary administration schedule. However, a dose of 50 mg twice daily is mandated for patients with documented or suspected INSTI resistance or when the medicine is co-administered with specific metabolic-inducing agents (e.g., rifampin).

Contextual Use Requirements

Dolutegravir film-coated tablets can be taken with or without food. If the patient has documented INSTI resistance, the tablet should preferably be taken with food to optimize drug exposure.

A critical procedural requirement involves the timing of administration relative to supplements. Dolutegravir must be separated by 2 hours before or 6 hours after taking polyvalent cation-containing products, such as iron, calcium supplements, or antacids. This separation is not required if the medicine and the supplement are taken simultaneously with a meal.

Administration for Specific Populations

Administration in pediatric patients is determined by specific weight bands, with use approved for children weighing 3 kg or more. Dispersible tablets are used for younger children and must be fully dispersed in drinking water; they must not be chewed or swallowed whole. If a dose is missed, it should be taken immediately, provided the next scheduled dose is not due within 4 hours. The treatment is continuous and long-term, not administered in cycles.

Research Evidence / Overview of Studies for Dolutegravir

---

Evidence for Initial HIV-1 Treatment (Treatment-Naive)

Research examining Dolutegravir as a first-line therapy primarily involved several large, high-level Randomized Controlled Trials (RCTs) that evaluated the regimens for potential use as initial therapy. Researchers explored the outcomes related to virologic suppression (viral load) and immunological recovery (CD4+ cell changes). These studies reported data collected on virologic and immunologic outcomes in observed populations of treatment-naive adults and adolescents, with follow-up durations typically extending from 48 weeks to approximately three years (144 weeks). Real-world observational studies also examined treatment adherence and retention outside the controlled trial environment.

---

Evidence for Changing or Second-Line HIV-1 Treatment

Studies have also examined the role of Dolutegravir for individuals who switched from a previous regimen, which included those who maintained viral control or those who experienced virologic non-suppression. Research explored how virologic outcomes were measured after the switch or second-line initiation. The studies monitored outcomes such as sustained virologic suppression and documented the incidence of acquired integrase resistance mutations in participants previously treated who had high viral loads. This body of evidence describes symptom patterns in individuals who required a change in their antiretroviral regimen.

---

Long-Term Studies, Special Populations, and Uncertainty

A key focus of research has been to monitor the durability of the virologic response over several years, utilizing extended follow-up phases and ongoing observational studies. The available evidence, which includes extension phase data, documents long-term follow-up for HIV-1 infection. Research has also examined the compound in special populations, including children and adolescents and pregnant women with HIV-1 infection. Despite this, certain aspects are still emerging. Long-term effects are not fully established concerning metabolic changes and patterns of weight gain, as the follow-up durations were limited for describing these outcomes over a decade or more. Findings were mixed when comparing results from controlled trials versus real-world cohort studies, highlighting that research is ongoing in several key areas.

Key Studies & References WHO Model List of Essential Medicines for Children (EMLc) - Dolutegravir 10mg Scored Dispersible Tablets

Common questions about Dolutegravir (FAQ)

Q: What is Dolutegravir and what is it used for?

Dolutegravir is an antiretroviral medicine used to treat HIV-1 infection. It belongs to a class of drugs called integrase strand transfer inhibitors (INSTIs).

It works by blocking an HIV enzyme called integrase, which the virus needs to multiply in the body. By stopping the virus from multiplying, Dolutegravir helps to reduce the amount of HIV in the blood (viral load) and increase the number of CD4+ T-cells, which are important for the immune system. Dolutegravir is always used in combination with other antiretroviral medicines.

Q: How should I take Dolutegravir?

Always take Dolutegravir exactly as your healthcare provider tells you.

• It is usually taken once a day.
• You can take it with or without food.
• If you are taking certain other medications, such as carbamazepine, oxcarbazepine, phenytoin, phenobarbital, or rifampin, your doctor may prescribe a higher dosage of Dolutegravir (twice a day).
• Swallow the tablet whole. Do not chew, crush, or split the tablet.

Important: If you are taking certain antacids (containing aluminum or magnesium) or supplements (containing calcium or iron), they must be taken at least 2 hours before or 6 hours after you take Dolutegravir. This is because these substances can reduce the amount of Dolutegravir absorbed by your body.

Q: What should I do if I miss a dose of Dolutegravir?

If you realize you missed a dose of Dolutegravir:

• If it has been less than 12 hours since your scheduled dose, take the missed dose right away. Then, take your next dose at the regular time.
• If it has been more than 12 hours since your scheduled dose, skip the missed dose and continue with your regular dosing schedule.

Do not take a double dose to make up for a missed dose. Missing doses can increase the risk of the virus becoming resistant to the medication.

Dolutegravir must be stored and handled according to specific regulatory requirements to maintain product integrity.

Storage Category	Requirement
Temperature Range	Store at room temperature (20 C to 25 C / 68 F to 77 F), with excursions permitted up to 30 C (86 F). Keep from freezing.
Protection	Store in the original container and keep tightly closed, protected from moisture. If a desiccant (drying agent) is present, it must not be removed.
Child Safety	Keep this medication and all medicines out of the sight and reach of children.

Unused or expired product must be safely discarded. The preferred method for disposal is a drug take-back program or mail-back option. If these are unavailable, disposal must be done by mixing the medicine with an unpalatable substance (like dirt or coffee grounds) and sealing the mixture in a container before discarding it in the household trash. Do not flush the medicine down the toilet.